Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era. - Fasser D; Lewis K; Leslie C; Cull G; Radeski D; Augustson B; Howman R; Joske D; Crawford J; Grove C; Cheah CY (Leukemia & lymphoma, 2025)